Literature DB >> 29180397

ApoL1 Overexpression Drives Variant-Independent Cytotoxicity.

John F O'Toole1,2,3, William Schilling4,5, Diana Kunze4, Sethu M Madhavan4, Martha Konieczkowski4, Yaping Gu2, Liping Luo2, Zhenzhen Wu2, Leslie A Bruggeman1,2,3, John R Sedor1,2,3,5.   

Abstract

Coding variants in the APOL1 gene are associated with kidney diseases in African ancestral populations; yet, the underlying biologic mechanisms remain uncertain. Variant-dependent autophagic and cytotoxic cell death have been proposed as pathogenic pathways mediating kidney injury. To examine this possibility, we conditionally expressed APOL1-G0 (reference), -G1, and -G2 (variants) using a tetracycline-regulated system in HEK293 cells. Autophagy was monitored biochemically and cell death was measured using multiple assays. We measured intracellular Na+ and K+ content with atomic absorption spectroscopy and APOL1-dependent currents with whole-cell patch clamping. Neither reference nor variant APOL1s induced autophagy. At high expression levels, APOL1-G0, -G1, and -G2 inserted into the plasma membrane and formed pH-sensitive cation channels, causing collapse of cellular Na+ and K+ gradients, phosphorylation of p38 mitogen-activated protein kinase, and cell death, without variant-dependent differences. APOL1-G0 and -G2 exhibited similar channel properties in whole-cell patch clamp experiments. At low expression levels, neither reference nor variant APOL1s localized on the plasma membrane, Na+ and K+ gradients were maintained, and cells remained viable. Our results indicate that APOL1-mediated pore formation is critical for the trypanolytic activity of APOL1 and drives APOL1-mediated cytotoxicity in overexpression systems. The absence of cytotoxicity at physiologic expression levels suggests variant-dependent intracellular K+ loss and cytotoxicity does not drive kidney disease progression.
Copyright © 2018 by the American Society of Nephrology.

Entities:  

Keywords:  autophagy; cell death; genetic renal disease; kidney

Mesh:

Substances:

Year:  2017        PMID: 29180397      PMCID: PMC5827587          DOI: 10.1681/ASN.2016121322

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  49 in total

1.  Autosis is a Na+,K+-ATPase-regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxia-ischemia.

Authors:  Yang Liu; Sanae Shoji-Kawata; Rhea M Sumpter; Yongjie Wei; Vanessa Ginet; Liying Zhang; Bruce Posner; Khoa A Tran; Douglas R Green; Ramnik J Xavier; Stanley Y Shaw; Peter G H Clarke; Julien Puyal; Beth Levine
Journal:  Proc Natl Acad Sci U S A       Date:  2013-11-25       Impact factor: 11.205

2.  Transgenic expression of human APOL1 risk variants in podocytes induces kidney disease in mice.

Authors:  Pazit Beckerman; Jing Bi-Karchin; Ae Seo Deok Park; Chengxiang Qiu; Patrick D Dummer; Irfana Soomro; Carine M Boustany-Kari; Steven S Pullen; Jeffrey H Miner; Chien-An A Hu; Tibor Rohacs; Kazunori Inoue; Shuta Ishibe; Moin A Saleem; Matthew B Palmer; Ana Maria Cuervo; Jeffrey B Kopp; Katalin Susztak
Journal:  Nat Med       Date:  2017-02-20       Impact factor: 53.440

3.  Apolipoprotein L-I is the trypanosome lytic factor of human serum.

Authors:  Luc Vanhamme; Françoise Paturiaux-Hanocq; Philippe Poelvoorde; Derek P Nolan; Laurence Lins; Jan Van Den Abbeele; Annette Pays; Patricia Tebabi; Huang Van Xong; Alain Jacquet; Nicole Moguilevsky; Marc Dieu; John P Kane; Patrick De Baetselier; Robert Brasseur; Etienne Pays
Journal:  Nature       Date:  2003-03-06       Impact factor: 49.962

4.  Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches.

Authors:  O P Hamill; A Marty; E Neher; B Sakmann; F J Sigworth
Journal:  Pflugers Arch       Date:  1981-08       Impact factor: 3.657

5.  The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival.

Authors:  B T Lee; V Kumar; T A Williams; R Abdi; A Bernhardy; C Dyer; S Conte; G Genovese; M D Ross; D J Friedman; R Gaston; E Milford; M R Pollak; A Chandraker
Journal:  Am J Transplant       Date:  2012-04-04       Impact factor: 8.086

6.  APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy.

Authors:  Jeffrey B Kopp; George W Nelson; Karmini Sampath; Randall C Johnson; Giulio Genovese; Ping An; David Friedman; William Briggs; Richard Dart; Stephen Korbet; Michele H Mokrzycki; Paul L Kimmel; Sophie Limou; Tejinder S Ahuja; Jeffrey S Berns; Justyna Fryc; Eric E Simon; Michael C Smith; Howard Trachtman; Donna M Michel; Jeffrey R Schelling; David Vlahov; Martin Pollak; Cheryl A Winkler
Journal:  J Am Soc Nephrol       Date:  2011-10-13       Impact factor: 10.121

7.  Localization of APOL1 protein and mRNA in the human kidney: nondiseased tissue, primary cells, and immortalized cell lines.

Authors:  Lijun Ma; Gregory S Shelness; James A Snipes; Mariana Murea; Peter A Antinozzi; Dongmei Cheng; Moin A Saleem; Simon C Satchell; Bernhard Banas; Peter W Mathieson; Matthias Kretzler; Ashok K Hemal; Lawrence L Rudel; Snezana Petrovic; Allison Weckerle; Martin R Pollak; Michael D Ross; John S Parks; Barry I Freedman
Journal:  J Am Soc Nephrol       Date:  2014-07-10       Impact factor: 10.121

8.  APOL1-G0 or APOL1-G2 Transgenic Models Develop Preeclampsia but Not Kidney Disease.

Authors:  Leslie A Bruggeman; Zhenzhen Wu; Liping Luo; Sethu M Madhavan; Martha Konieczkowski; Paul E Drawz; David B Thomas; Laura Barisoni; John R Sedor; John F O'Toole
Journal:  J Am Soc Nephrol       Date:  2016-03-29       Impact factor: 10.121

9.  Plasma Levels of Risk-Variant APOL1 Do Not Associate with Renal Disease in a Population-Based Cohort.

Authors:  Julia Kozlitina; Haihong Zhou; Patricia N Brown; Rory J Rohm; Yi Pan; Gulesi Ayanoglu; Xiaoyan Du; Eric Rimmer; Dermot F Reilly; Thomas P Roddy; Doris F Cully; Thomas F Vogt; Daniel Blom; Maarten Hoek
Journal:  J Am Soc Nephrol       Date:  2016-03-22       Impact factor: 10.121

10.  APOL1 renal risk variants have contrasting resistance and susceptibility associations with African trypanosomiasis.

Authors:  Anneli Cooper; Hamidou Ilboudo; V Pius Alibu; Sophie Ravel; John Enyaru; William Weir; Harry Noyes; Paul Capewell; Mamadou Camara; Jacqueline Milet; Vincent Jamonneau; Oumou Camara; Enock Matovu; Bruno Bucheton; Annette MacLeod
Journal:  Elife       Date:  2017-05-24       Impact factor: 8.140

View more
  37 in total

1.  Apolipoprotein L1 (APOL1) risk variant toxicity depends on the haplotype background.

Authors:  Herbert Lannon; Shrijal S Shah; Leny Dias; Daniel Blackler; Seth L Alper; Martin R Pollak; David J Friedman
Journal:  Kidney Int       Date:  2019-08-01       Impact factor: 10.612

Review 2.  APOL1: The Balance Imposed by Infection, Selection, and Kidney Disease.

Authors:  Pazit Beckerman; Katalin Susztak
Journal:  Trends Mol Med       Date:  2018-06-07       Impact factor: 11.951

3.  APOL1 Kidney Risk Variants Induce Cell Death via Mitochondrial Translocation and Opening of the Mitochondrial Permeability Transition Pore.

Authors:  Shrijal S Shah; Herbert Lannon; Leny Dias; Jia-Yue Zhang; Seth L Alper; Martin R Pollak; David J Friedman
Journal:  J Am Soc Nephrol       Date:  2019-09-26       Impact factor: 10.121

4.  Disrupted apolipoprotein L1-miR193a axis dedifferentiates podocytes through autophagy blockade in an APOL1 risk milieu.

Authors:  Vinod Kumar; Kamesh Ayasolla; Alok Jha; Abheepsa Mishra; Himanshu Vashistha; Xiqian Lan; Maleeha Qayyum; Sushma Chinnapaka; Richa Purohit; Joanna Mikulak; Moin A Saleem; Ashwani Malhotra; Karl Skorecki; Pravin C Singhal
Journal:  Am J Physiol Cell Physiol       Date:  2019-05-22       Impact factor: 4.249

5.  Apolipoprotein L-1 renal risk variants form active channels at the plasma membrane driving cytotoxicity.

Authors:  Joseph A Giovinazzo; Russell P Thomson; Nailya Khalizova; Patrick J Zager; Nirav Malani; Enrique Rodriguez-Boulan; Jayne Raper; Ryan Schreiner
Journal:  Elife       Date:  2020-05-19       Impact factor: 8.140

6.  The Mechanism of Kidney Disease Due to APOL1 Risk Variants.

Authors:  Etienne Pays
Journal:  J Am Soc Nephrol       Date:  2020-09-17       Impact factor: 10.121

7.  Kidney Disease-Associated APOL1 Variants Have Dose-Dependent, Dominant Toxic Gain-of-Function.

Authors:  Somenath Datta; Rama Kataria; Jia-Yue Zhang; Savannah Moore; Kaitlyn Petitpas; Adam Mohamed; Nathan Zahler; Martin R Pollak; Opeyemi A Olabisi
Journal:  J Am Soc Nephrol       Date:  2020-07-16       Impact factor: 10.121

8.  Domain-Specific Antibodies Reveal Differences in the Membrane Topologies of Apolipoprotein L1 in Serum and Podocytes.

Authors:  Nidhi Gupta; Xinhua Wang; Xiaohui Wen; Paul Moran; Maciej Paluch; Philip E Hass; Amy Heidersbach; Benjamin Haley; Daniel Kirchhofer; Randall J Brezski; Andrew S Peterson; Suzie J Scales
Journal:  J Am Soc Nephrol       Date:  2020-08-06       Impact factor: 10.121

9.  Apolipoprotein L1-Specific Antibodies Detect Endogenous APOL1 inside the Endoplasmic Reticulum and on the Plasma Membrane of Podocytes.

Authors:  Suzie J Scales; Nidhi Gupta; Ann M De Mazière; George Posthuma; Cecilia P Chiu; Andrew A Pierce; Kathy Hötzel; Jianhua Tao; Oded Foreman; Georgios Koukos; Francesca Oltrabella; Judith Klumperman; WeiYu Lin; Andrew S Peterson
Journal:  J Am Soc Nephrol       Date:  2020-08-06       Impact factor: 10.121

Review 10.  Apolipoprotein L1 nephropathies: 2017 in review.

Authors:  Jeffrey B Kopp; Hila Roshanravan; Koji Okamoto
Journal:  Curr Opin Nephrol Hypertens       Date:  2018-05       Impact factor: 2.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.